Half-year report · HY
4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.2bn | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥18.5bn | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥8.5bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥2.5bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥5.3bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥2.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥72.2bn | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥77.0bn | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥78.5bn | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥23.7bn | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥25.5bn | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥48.6bn | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥51.5bn | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥53.7bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥48.6bn | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥51.5bn | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥53.7bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥23.6bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥28.7bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.8bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥13.3bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥11.0bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥614m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥4.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.2% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.9% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.3% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥512m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥512m |
| Drug Discovery And Development Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥2.7bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥8.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥8.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥242m |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥9.7bn |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥9.2bn |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | −¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥453m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥453m |
| Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥3.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥7.8bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥436m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥9.0bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 571
| Item | Context | Value | Unit |
|---|---|---|---|
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂一丁目８番１号 | |
| Name major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)窪田 規一 | |
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)東京都目黒区 | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)菅 裕明 | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)東京都文京区 | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目８番12号 | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)村上 裕 | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)愛知県名古屋市千種区 | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)リード・パトリック | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)千葉県木更津市 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)8 CANADA SQUARE, LONDON E14 5HQ（東京都中央区日本橋３丁目） | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)株式会社SBI証券 | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)東京都港区六本木１丁目６番１号 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Text · Plus | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)ペプチドリーム株式会社 | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |